| Q22241922 | 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
| Q38672923 | A Safety Evaluation of Cangrelor in Patients Undergoing PCI. |
| Q26777116 | Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions |
| Q37059195 | Antiplatelet agents in clinical practice and their haemorrhagic risk. |
| Q37965609 | Antiplatelet therapy in acute coronary syndromes. |
| Q39472608 | Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy |
| Q36952116 | BLEED-Myocardial Infarction Score: Predicting mid-term post-discharge bleeding events |
| Q28256871 | Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial |
| Q37851949 | Bivalirudin: a pharmacoeconomic profile of its use in patients with acute coronary syndromes |
| Q56837753 | Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center |
| Q85096156 | Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy |
| Q36882607 | Bleeding-avoidance strategies and outcomes in patients ≥80 years of age with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the NCDR CathPCI Registry). |
| Q52643133 | Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. |
| Q41643200 | Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome |
| Q39940185 | Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel |
| Q48165705 | Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome |
| Q64101522 | Development and Validation of a Novel Risk Score for In-Hospital Major Bleeding in Acute Myocardial Infarction:-The SWEDEHEART Score |
| Q34531925 | Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study |
| Q91787892 | Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting |
| Q33797609 | Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies |
| Q44172490 | Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil |
| Q37888541 | How serious a problem is bleeding in patients with acute coronary syndromes? |
| Q38051154 | Identifying, monitoring and reducing preventable major bleeds in the hospital setting |
| Q92456065 | Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial |
| Q50662100 | Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibiti |
| Q104111247 | Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease |
| Q41708497 | Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials |
| Q40890811 | Impact of transradial coronary intervention on bleeding complications in octogenarians |
| Q35193938 | Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention |
| Q36927607 | Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study |
| Q34333274 | Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis |
| Q33814243 | Major bleeding events in Jordanian patients undergoing percutaneous coronary intervention (PCI): Incidence, associated factors, impact on prognosis, and predictability of the CRUSADE bleeding risk score. Results from the First Jordanian PCR (PCR1) |
| Q37141014 | Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of ANTithRombotic Agents: the MANTRA registry |
| Q58841190 | Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting |
| Q38379410 | Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study |
| Q38005012 | New anticoagulants in ischemic heart disease |
| Q45018958 | One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel |
| Q38063290 | Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. |
| Q43102079 | Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk |
| Q64939825 | Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. |
| Q86814458 | Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry |
| Q40642186 | Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry |
| Q38107887 | Patients who require non-cardiac surgery in acute coronary syndrome |
| Q55000647 | Patterns of in-hospital mortality and bleeding complications following PCI for very elderly patients: insights from the Dartmouth Dynamic Registry. |
| Q38672873 | Percutaneous coronary interventions and antiplatelet therapy in renal transplant recipients |
| Q22241918 | Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention |
| Q38305495 | Predicting and preventing vascular complications following percutaneous coronary intervention in women |
| Q40825580 | Prediction and impact of failure of transradial approach for primary percutaneous coronary intervention |
| Q39619295 | Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials |
| Q57396237 | Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction |
| Q57764402 | Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation |
| Q38340126 | Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention |
| Q44640403 | Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction |
| Q37837981 | Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction |
| Q84330048 | Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis |
| Q33391484 | Safety and tolerability of high-intensity anticoagulation with bivalirudin during neuroendovascular procedures |
| Q58759145 | Sepsis as an important risk factor for gastrointestinal bleeding in acute coronary syndrome patients: Two case reports |
| Q34492675 | Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium |
| Q88195960 | The Role of the Transradial Approach for Complex Coronary Interventions in Patients with Acute Coronary Syndrome |
| Q36162429 | The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction |
| Q43283675 | The changing horizon of acute coronary syndrome |
| Q37923969 | The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders |
| Q38603459 | The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review |
| Q43525435 | The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel |
| Q43192530 | Ticagrelor in ACS: redefining a new standard of care? |
| Q37807874 | Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome |
| Q50204823 | Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial |
| Q88195793 | Transradial Approach in Primary Percutaneous Coronary Intervention: Lessons from a High-volume Centre |
| Q33599555 | Transradial versus transfemoral approach in patients undergoing percutaneous coronary intervention for acute coronary syndrome. A meta-analysis and trial sequential analysis of randomized controlled trials |
| Q40126443 | Transradial versus transfemoral approach in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction: insight from the CREDO-Kyoto AMI registry |
| Q36417654 | Transulnar sheathless percutaneous coronary intervention during bivalirudin infusion in high-risk elderly female with non-ST segment elevation myocardial infarction. |
| Q51805253 | Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review. |
| Q43267571 | Underestimation of the effect of bleeding in clinical trials |
| Q38118745 | Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice |
| Q37699642 | Vascular complications after transcatheter aortic valve implantation (TAVI): risk and long-term results |
| Q47173271 | Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention |
| Q41904786 | Welcome to the ESC journal family |
| Q83179013 | [Ischemic heart disease: 2009 update] |
| Q22242895 | ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el |